GlassScriptPhysician profile
Daniel J Daire
NPI 1972967610
$6,457.50
in general payments reported to CMS, 2019-2025
39 companies · $1,987 in 2025
The $1,987 reported for 2025 was more than what 95% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $452 · 2022: $634 · 2023: $2,068 · 2024: $1,317 · 2025: $1,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,372.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,371.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,097.16 | 2021-2025 | |
| Lilly USA, LLC | $791.91 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $596.45 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $459.38 | 2021-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $449.75 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $308.46 | 2022-2025 | |
| Amgen INC. | $267.59 | 2021-2025 | Repatha, Otezla, Evenity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $262.62 | 2022-2025 | Trulance, Xifaxan |
| Astellas Pharma US INC | $230.45 | 2023-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $208.69 | 2021-2025 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $207.47 | 2025 | Rexulti |
| Lundbeck LLC | $206.01 | 2025 | Vyepti, Rexulti |
| Exact Sciences Corporation | $194.28 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sumitomo Pharma America, INC. | $184.59 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.08 | 2021-2025 | Jardiance, Tradjenta |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Daire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.